Form 4: Myriad Genetics Chief People Officer Reports Stock Transactions
SEC Form 4 Filing
Shereen Solaiman, Chief People Officer of Myriad Genetics, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.
Summary
- On March 13, 2025, Shereen Solaiman, Chief People Officer of Myriad Genetics, acquired 63,145 shares of common stock in the form of restricted stock units.
- These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
- On March 14, 2025, Ms. Solaiman disposed of 6,060 shares of common stock at a price of $10.07 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
- Following these transactions, Ms. Solaiman beneficially owns 110,963 shares of Myriad Genetics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects standard executive compensation practices and tax-related transactions. There are no overtly positive or negative implications.
Positives
- The acquisition of restricted stock units indicates confidence in the company's future performance.
Negatives
- The sale of shares to cover tax obligations, while routine, slightly reduces the officer's holdings.
Risks
- There are no specific risks highlighted in this document.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the restricted stock units suggests a multi-year commitment from the executive.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices.
Comparison to Industry Standards
- Stock-based compensation is a common practice in the biotechnology industry to align management's interests with those of shareholders.
- Vesting schedules of three years are typical for restricted stock units.
- Comparable companies such as Exact Sciences and Illumina also utilize similar equity compensation plans for their executives.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- They reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Grant date of 63,145 restricted stock units. |
| 03/14/2025 | Disposition of 6,060 shares to cover tax obligations. |
| 03/17/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.